Document is current
Any future updates will be listed below
-
Authors
Sun, Junyu https://orcid.org/0000-0001-5532-3593
Zelaya, Fernando https://orcid.org/0000-0002-9525-1560
Sendt, Kyra-Verena
McQueen, Grant
Gillespie, Amy L. https://orcid.org/0000-0003-4640-699X
Lally, John
Howes, Oliver D. https://orcid.org/0000-0002-2928-1972
Barker, Gareth J. https://orcid.org/0000-0002-5214-7421
McGuire, Philip https://orcid.org/0000-0003-4381-0532
MacCabe, James H. https://orcid.org/0000-0002-6754-1018
Egerton, Alice https://orcid.org/0000-0003-2939-064X
- License Information
-
More Information
Article History
Received: 9 October 2024
Accepted: 26 November 2024
First Online: 23 December 2024
Competing interests
: A.L.G. has received consultancy fees from Zogenix/UCB. A.E. has received consultancy fees from Leal Therapeutics. O.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neurocrine, Ontrack/ Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi and Viatris/Mylan. He was previously a part-time employee of Lundbeck A/v, and has a patent for the use of dopaminergic imaging. G.J.B. has received honoraria for teaching from GE Healthcare. J.H.M. has received investigator-initiated research funding from H Lundbeck. He has received research funding for clinical trials from H Lundbeck and Karuna Therapeutics, and has participated in advisory boards for H Lundbeck, LB Pharma, Newron Pharmaceuticals and Teva UK Ltd. The remaining authors declare no competing interest.
